Press Releases

Press Releases

News, Events, Updates, Breakthroughs

Journalists may direct questions to Or click here for direct contact information for Daiichi Sankyo U.S. Public Affairs team

Press announcements are archived by release date, searchable by topic:

From To
Date Title
Daiichi Sankyo Announces Single Agent Quizartinib Significantly Prolongs Overall Survival Compared ...
PDF (268 KB)
Zymeworks and Daiichi Sankyo Expand Immuno-Oncology Collaboration Focused on Bispecific Antibodies
PDF (171 KB)
Daiichi Sankyo to Present New Data on Multiple Compounds Including Antibody Drug Conjugates DS-8201 ...
PDF (295 KB)
Daiichi Sankyo Initiates Phase 2 Study of DS-8201 in Patients with Advanced HER2-Overexpressing or ...
PDF (189 KB)
Daiichi Sankyo Presents Long-Term Phase 1 Results of Antibody Drug Conjugate DS-8201 in Patients wi ...
PDF (203 KB)
Daiichi Sankyo Presents Preliminary Phase 1 Data for Antibody Drug Conjugate U3-1402 in Patients wi ...
PDF (271 KB)
Daiichi Sankyo Presents Phase 3 ENLIVEN Study of Pexidartinib, Demonstrating Statistically Signific ...
PDF (132 KB)
Daiichi Sankyo’s U.S. Products Liability Litigation Settlement Program Moves Forward; More than 97 ...
PDF (166 KB)
Daiichi Sankyo to Present Late-Breaking Phase 3 Data for Single Agent Quizartinib in Patients with ...
PDF (190 KB)
Phase 3 QuANTUM-R Study Demonstrates Daiichi Sankyo’s Quizartinib Significantly Prolongs Overall Su ...
PDF (246 KB)
Showing 1 - 10 of 47 results.

Press Release More Stories

More Stories

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability..

read more ...